Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Company Overview

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Key Stats

• Today's Range: $1.16 to $1.27
• 50-Day Range: $0.93 to $1.84
• 52-Week Range: $0.45 to $3.80
• Volume: 22,372 shs
• Average Volume: 438,042 shs
• Market Capitalization: $7.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Chromocell Therapeutics Stock Analysis - MarketRank™

Chromocell Therapeutics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Chromocell Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Chromocell Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chromocell Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.24% of the float of Chromocell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chromocell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chromocell Therapeutics has recently decreased by 28.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chromocell Therapeutics does not currently pay a dividend.

Dividend Growth

Chromocell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.24% of the float of Chromocell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chromocell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chromocell Therapeutics has recently decreased by 28.10%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

Chromocell Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Chromocell Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chromocell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.40% of the stock of Chromocell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.96% of the stock of Chromocell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CHRO Stock Analysis - Frequently Asked Questions

How have CHRO shares performed this year?

Chromocell Therapeutics' stock was trading at $0.6410 at the start of the year. Since then, CHRO stock has increased by 85.6% and is now trading at $1.19.
View the best growth stocks for 2025 here.

When did Chromocell Therapeutics IPO?

Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at a price of $6.00 per share.

How do I buy shares of Chromocell Therapeutics?

Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CHRO
• Previous Symbol: NYSE:CHRO
• CIK: 1919246
• Web: chromocell.com
• Phone: 732-514-2636
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -453.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.65) per share
• Price / Book: -0.72

Miscellaneous

• Outstanding Shares: 6,596,000
• Free Float: 5,039,000
• Market Cap: $7.85 million
• Optionable: N/A
• Beta: 3.22